Who owns the IP
The organizations most actively patenting around this compound, ranked by referenced patent volume.
| # | Assignee | Patents |
|---|---|---|
| 1 | ModernaTx Inc | 374 |
| 2 | Curevac SE | 249 |
| 3 | GlaxoSmithKline Biologicals SA | 129 |
| 4 | Pangu Biopharma Ltd | 123 |
| 5 | aTyr Pharma Inc | 117 |
| 6 | University of Pennsylvania | 83 |
| 7 | Moderna Inc | 79 |
| 8 | Thermo Fisher Scientific Inc | 72 |
| 9 | Harvard University | 69 |
| 10 | Dharmacon Inc | 61 |
Explore the full landscape
This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.
Visit CyprisWhere innovation is concentrated
Patent classifications ranked by volume reveal the technical domains with the most active filing.
| # | Code | Area | Patents |
|---|---|---|---|
| 1 | C12N | Microorganisms, enzymes | 3,222 |
| 2 | A61K | Medicinal preparations | 3,133 |
| 3 | A61P | Therapeutic activity (drug indications) | 2,655 |
| 4 | C07K | Peptides | 1,500 |
| 5 | C12Q | Measuring/testing involving enzymes | 705 |
| 6 | C12Y | Enzyme nomenclature (EC numbers) | 671 |
| 7 | G01N | Investigating / analysing materials | 596 |
| 8 | C07H | Sugars and derivatives | 447 |
| 9 | Y02A | Climate change adaptation | 404 |
| 10 | C12P | Fermentation, enzyme processes | 259 |
AI mapped opportunity space
This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.
See Cypris in actionWhere research is gaining momentum
Research themes ranked by publication activity show where scientific interest is accelerating around this compound.
| # | Research topic | Papers |
|---|---|---|
| 1 | Geography and Environmental Studies | 1 |
| 2 | RNA and protein synthesis mechanisms | 1 |
| 3 | RNA modifications and cancer | 1 |
Who's driving the science
The most-published authors working with this compound, alongside their primary affiliations.
| # | Author | Affiliation | Papers |
|---|---|---|---|
| 1 | Michinao Mizugaki | Tohoku University Hospital | 10 |
| 2 | Kunihiko Itoh | Tohoku University Hospital | 9 |
| 3 | Nakao Ishida | Tohoku University | 9 |
| 4 | Chengqi Yi | Peking University | 5 |
| 5 | Chuan He | University of Chicago | 5 |
| 6 | Qing Dai | University of Chicago | 5 |
| 7 | Shunji Ishiwata | Tohoku University Hospital | 5 |
| 8 | Claudia Höbartner | University of Würzburg | 3 |
| 9 | Dan Dominissini | Tel Aviv University | 3 |
| 10 | Eikan Mishima | Tohoku University | 3 |
Research leaders
This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.
See Cypris in actionThe literature that defines it
The most-cited papers anchoring the scientific record for this compound.
| Title | Year | Cited by | Topic |
|---|---|---|---|
| Post-transcriptional gene regulation by mRNA modifications | 2016 | 2551 | RNA and protein synthesis mechanisms |
| The dynamic N1-methyladenosine methylome in eukaryotic messenger RNA | 2016 | 1053 | RNA and protein synthesis mechanisms |
| Transcriptome-wide mapping reveals reversible and dynamic N1-methyladenosine methylome | 2016 | 710 | Cancer-related molecular mechanisms research |
| The m1A landscape on cytosolic and mitochondrial mRNA at single-base resolution | 2017 | 663 | Cancer-related molecular mechanisms research |
| ALKBH1-Mediated tRNA Demethylation Regulates Translation | 2016 | 592 | Epigenetics and DNA Methylation |
Frequently asked questions
Common questions about this compound's patent and research landscape, answered from the underlying data.
What is the molecular composition of alpha-Vetivone?
Which organizations hold the most patents related to alpha-Vetivone?
What research areas dominate the patent landscape for alpha-Vetivone?
What are the most cited papers associated with alpha-Vetivone research?
How has patent activity around alpha-Vetivone evolved in recent years?